Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

CSBR

Champions

NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.46

-0.23

-1.97%

After Hours: 11.46 0 0.00% 16:00 02/25 EST

OPEN

11.60

PREV CLOSE

11.69

HIGH

11.79

LOW

11.21

VOLUME

13.02K

TURNOVER

52 WEEK HIGH

13.45

52 WEEK LOW

4.020

MARKET CAP

153.21M

P/E (TTM)

-88.2897

News

Financial

Releases

Corp Actions

Analysis

Profile

Champions Oncology Announces Addition to Board of Directors

HACKENSACK, NJ / ACCESSWIRE / February 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR) a leading global oncology technology solutions provider transforming drug discovery through innovative pharmacology, biomarker, and data platforms, is pleased to annou...

ACCESSWIRE · 3d ago

Humanized Mouse Model Market Growth 2021 CAGR Value, Analysis by Size, Share, Top Key Players, Latest Trends and Forecast to 2024

Feb 18, 2021 (The Expresswire) -- “Humanized Mouse Model Market” report provides key statistics on the market status of the Humanized Mouse Model...

The Express Wire · 02/18 08:13

8-K: CHAMPIONS ONCOLOGY, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE...

Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/13 02:20

COVID-19 Business Impact: Patient Derived Xenograft PDX Models Market Hierarchy of Needs -Moving from Pandemic Risk Management to Organizational Agility During 2025

AmericaNewsHour · 02/10 14:31

Humanized Mouse Model Market Terms and Agreements 2021-2025: Deal Trends, Players and Financials

Feb 10, 2021 (AmericaNewsHour) -- The global Humanized Mouse Model Market was valued at USD 73.21 million in 2016 and is projected to reach USD 166.24...

AmericaNewsHour · 02/10 11:32

Global Patient Derived Xenograft Models Market 2020 with COVID-19 After Effects - Growth Drivers, Top Key Players, Industry Segments and Forecast to 2025

Feb 03, 2021 (CDN Newswire via Comtex) -- Global Patient Derived Xenograft Models Market 2020 by Manufacturers, Regions, Type and Application, Forecast to...

CDN Newswire · 02/03 19:02

Global Patient Derived Xenograft Models Market 2020 Ecosystem Player Profiles, Value Chain and Industry Strategies to 2025

Feb 01, 2021 (CDN Newswire via Comtex) -- Global Patient Derived Xenograft Models Market 2020 by Manufacturers, Type and Application, Forecast to 2025...

CDN Newswire · 02/02 04:23

Can You Imagine How Jubilant Champions Oncology's (NASDAQ:CSBR) Shareholders Feel About Its 220% Share Price Gain?

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Simply Wall St. · 01/29 05:24

Forecast

EPSBVPSCFPS

Actual (USD)

Estimate (USD)

Income StatementMore

Net IncomeTotal RevenueOperating Income

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

OperatingInvestingFinancing

Operating (USD)

YoY (%)

Learn about the latest financial forecast of CSBR. Analyze the recent business situations of Champions through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CSBR stock price target is 13.83 with a high estimate of 14.00 and a low estimate of 13.50.

EPS

Institutional Holdings

Institutions: 72

Institutional Holdings: 10.08M

% Owned: 75.41%

Shares Outstanding: 13.37M

TypeInstitutionsShares

Increased

121.24K

New

2.73M

Decreased

340.40K

Sold Out

Performance
Asset Allocation
Dividend History

No Data

Industry

Biotechnology & Medical Research

-2.53%

Pharmaceuticals & Medical Research

-1.34%

Key Executives

Chairman/Director

Joel Ackerman

Chief Executive Officer/Director

Ronnie Morris

Chief Financial Officer

David Miller

Lead Director/Independent Director

David Sidransky

Director

Robert Brainin

Independent Director

Philip Breitfeld

Independent Director

Daniel Mendelson

Independent Director

Scott Tobin

Dividends
Splits
Insider Activity

No Data

All
Financials
Insiders

About CSBR

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.

Webull offers kinds of Champions Oncology Inc stock information, including NASDAQ:CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.